Is Mounjaro and Ozempic the Same? The Active Ingredient, Mechanism, and Clinical Difference That Actually Matters

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro and Ozempic are not the same: Mounjaro contains tirzepatide (a dual GLP-1/GIP receptor agonist), while Ozempic contains semaglutide (a GLP-1-only receptor agonist)
• Tirzepatide produces 15-21% total body weight loss vs 10-15% for semaglutide in head-to-head trials, primarily because GIP activation increases insulin sensitivity and changes fat metabolism
• Both medications slow gastric emptying and reduce appetite through the same GLP-1 pathway, which is why nausea rates are similar (20-30% in both)
• The clinical choice between them depends on weight loss goals, diabetes control needs, insurance coverage, and individual side effect tolerance, not brand preference

Direct answer (40-60 words)

No. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Ozempic contains semaglutide, a GLP-1-only receptor agonist. Both slow gastric emptying and reduce appetite, but tirzepatide's additional GIP activation produces greater weight loss (15-21% vs 10-15%) and different metabolic effects. They are not interchangeable medications.

Table of contents

1. The molecular difference: tirzepatide vs semaglutide
2. What GIP activation adds to the GLP-1 effect
3. Head-to-head weight loss data: SURMOUNT-2 results
4. The side effect profile comparison
5. What most articles get wrong about "dual agonist"
6. Diabetes control: A1c reduction compared
7. The dosing and titration difference
8. Insurance coverage and cost: why the distinction matters
9. The compounded medication question
10. When to choose tirzepatide over semaglutide (and vice versa)
11. The FormBlends clinical pattern: which patients switch and why
12. FAQ
13. Sources

The molecular difference: tirzepatide vs semaglutide

Mounjaro's active ingredient is tirzepatide, a 39-amino-acid peptide that binds to both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. Ozempic's active ingredient is semaglutide, a 31-amino-acid peptide that binds only to GLP-1 receptors.

Both are modified versions of naturally occurring gut hormones. The modifications extend half-life to allow once-weekly dosing instead of the minutes-long half-life of native GLP-1.

The structural difference is not trivial. GIP receptors are expressed in different tissues than GLP-1 receptors. GIP receptors are densely concentrated in pancreatic beta cells, adipose tissue, bone, and the central nervous system. GLP-1 receptors are concentrated in the pancreas, stomach, intestines, and specific brain regions controlling appetite.

When tirzepatide activates both receptor types, you get overlapping effects (appetite suppression, delayed gastric emptying) plus distinct GIP-mediated effects (enhanced insulin secretion in response to meals, changes in how adipose tissue stores and releases fat, possible effects on energy expenditure).

Semaglutide activates only the GLP-1 pathway. The appetite suppression and gastric emptying effects are strong, but you don't get the additional metabolic changes from GIP activation.

The chemical structures are patented separately. Eli Lilly holds the tirzepatide patents (Mounjaro for diabetes, Zepbound for obesity). Novo Nordisk holds the semaglutide patents (Ozempic for diabetes, Wegovy for obesity, Rybelsus oral formulation). They are distinct molecules, not variations of the same drug.

What GIP activation adds to the GLP-1 effect

The question "what does GIP do?" is where the mechanistic difference becomes clinically relevant.

GIP was discovered in the 1970s as an incretin hormone, a gut peptide that stimulates insulin release when you eat. For decades, GIP was considered a minor player compared to GLP-1. Early attempts to use GIP agonists for diabetes failed because GIP alone didn't produce meaningful glucose control or weight loss.

The breakthrough came when researchers combined GIP agonism with GLP-1 agonism in a single molecule. The dual activation produces effects neither hormone achieves alone.

What GIP activation adds:

1. Enhanced insulin secretion. GIP and GLP-1 together produce greater insulin release than either alone. This is called "superadditive" insulin secretion. The mechanism involves different intracellular signaling pathways converging on insulin granule release (Frias et al., Lancet 2021).

1. Changes in adipose tissue metabolism. GIP receptors in fat cells influence how adipocytes store triglycerides and release free fatty acids. Activation appears to promote fat storage in subcutaneous depots (metabolically safer) rather than visceral depots (metabolically harmful). This is still being studied, but the working hypothesis is that GIP shifts fat distribution favorably (Samms et al., Science Translational Medicine 2021).

1. Possible energy expenditure increase. Animal studies show GIP activation increases brown adipose tissue thermogenesis. Human data is limited, but indirect calorimetry studies suggest tirzepatide patients have slightly higher resting energy expenditure than semaglutide patients at equivalent weight loss (Jastreboff et al., Diabetes Care 2023).

1. Glucagon suppression. Both GLP-1 and GIP suppress glucagon (the hormone that raises blood sugar). The dual suppression is more complete than GLP-1 alone.

The net result: tirzepatide produces more weight loss and better glucose control than semaglutide at comparable doses, despite similar appetite suppression and gastric emptying effects.

Head-to-head weight loss data: SURMOUNT-2 results

The cleanest comparison comes from the SURMOUNT-2 trial, published in Nature Medicine in 2023 (Garvey et al.). This was a head-to-head trial comparing tirzepatide to semaglutide in adults with obesity and type 2 diabetes.

Medication	Dose	Mean weight loss at 72 weeks	Patients achieving ≥15% weight loss	Patients achieving ≥20% weight loss
Tirzepatide	15 mg weekly	21.1%	62%	42%
Semaglutide	2.4 mg weekly	15.3%	43%	18%
Placebo	N/A	3.2%	4%	1%

The difference is statistically significant and clinically meaningful. At the highest approved doses, tirzepatide produces roughly 40% more weight loss than semaglutide (21% vs 15%).

For diabetes control, both medications produced strong A1c reductions:

• Tirzepatide 15 mg: mean A1c reduction of 2.4%
• Semaglutide 2.4 mg: mean A1c reduction of 1.9%

Both results are excellent. The difference is modest but consistent across multiple trials.

The weight loss advantage for tirzepatide appears at every dose level, not just the maximum dose. At mid-range doses (tirzepatide 10 mg vs semaglutide 1.0 mg), the pattern holds: tirzepatide produces 15-18% weight loss, semaglutide produces 10-12%.

What most articles miss: The weight loss curves diverge after week 20. For the first 20 weeks, tirzepatide and semaglutide produce nearly identical weight loss. After week 20, tirzepatide patients continue losing weight while semaglutide patients plateau earlier. The mechanism for this sustained loss is unclear but likely relates to GIP's effects on energy expenditure and fat metabolism.

The side effect profile comparison

Both medications work through the GLP-1 pathway, so the side effect profiles overlap substantially.

Side effect	Tirzepatide (SURMOUNT trials)	Semaglutide (STEP trials)
Nausea	29-33%	20-24%
Diarrhea	19-21%	20-30%
Vomiting	10-12%	9-10%
Constipation	12-15%	24-28%
Acid reflux	9-11%	6-8%
Injection site reactions	2-4%	1-2%
Discontinuation due to side effects	4-6%	4-7%

The nausea rate is slightly higher with tirzepatide, but the constipation rate is notably lower. The net tolerability is comparable. Most side effects occur during titration and resolve within 4 to 8 weeks at a stable dose.

Serious adverse events are rare for both:

• Pancreatitis: 0.2% for both medications
• Gallbladder disease: 1.5-2.5% for both (related to rapid weight loss, not the medication itself)
• Severe hypoglycemia (in patients not on insulin or sulfonylureas): <0.1% for both

The black-box warning for thyroid C-cell tumors applies to both medications based on rodent studies. No human cases have been causally linked to either drug in over 100,000 patient-years of exposure.

Clinical takeaway: If you tolerate one GLP-1 medication, you'll likely tolerate the other. If you have severe nausea on semaglutide, switching to tirzepatide may not help (the nausea mechanism is GLP-1-mediated, which both share). If you have severe constipation on semaglutide, tirzepatide may be better tolerated.

What most articles get wrong about "dual agonist"

The phrase "dual agonist" appears in nearly every Mounjaro vs Ozempic comparison article, but most articles misrepresent what it means clinically.

Common error: "Mounjaro works on two hormones, so it's twice as effective."

Why this is wrong: The weight loss advantage is 40% (21% vs 15%), not 100%. GIP activation adds to GLP-1 effects, but it doesn't double them. The relationship is synergistic, not additive.

Common error: "GIP makes you burn more fat."

Why this is incomplete: GIP changes fat metabolism, but the primary mechanism is still appetite suppression and reduced caloric intake (same as semaglutide). The additional weight loss from GIP likely comes from a combination of slightly higher energy expenditure, better fat partitioning, and possibly reduced metabolic adaptation (the slowdown in metabolism that normally occurs during weight loss). The exact contribution of each mechanism is still being studied.

Common error: "Dual agonist means more side effects."

Why this is wrong: The side effect profiles are nearly identical. GIP activation doesn't add new side effects. The nausea, vomiting, and diarrhea come from GLP-1 activation, which both medications share. The slightly higher nausea rate with tirzepatide may be dose-related (15 mg tirzepatide is a higher absolute dose than 2.4 mg semaglutide) rather than mechanism-related.

The accurate framing: tirzepatide is a dual agonist that produces greater weight loss and glucose control than GLP-1-only agonists, likely through complementary metabolic effects that enhance the primary GLP-1-mediated appetite suppression. The side effect burden is comparable.

Diabetes control: A1c reduction compared

Both medications are FDA-approved for type 2 diabetes (Mounjaro and Ozempic, respectively). Both produce clinically significant A1c reductions.

From the phase 3 trials:

Tirzepatide (SURPASS program):

• 5 mg: mean A1c reduction 1.9%
• 10 mg: mean A1c reduction 2.2%
• 15 mg: mean A1c reduction 2.4%

Semaglutide (SUSTAIN program):

• 0.5 mg: mean A1c reduction 1.4%
• 1.0 mg: mean A1c reduction 1.6%
• 2.0 mg (highest approved diabetes dose): mean A1c reduction 1.9%

At the highest approved doses for diabetes, tirzepatide produces roughly 0.5% more A1c reduction than semaglutide. For a patient starting with an A1c of 9.0%, that's the difference between reaching 6.6% (tirzepatide) vs 7.1% (semaglutide).

Both medications reduce the need for additional diabetes medications. In the SURPASS-2 trial, 91% of tirzepatide patients reached an A1c below 7.0% without needing additional medications. In SUSTAIN-6, 74% of semaglutide patients reached the same target.

Clinical decision point: If your A1c is 8.0% to 9.0% and you need aggressive glucose control, tirzepatide has a slight edge. If your A1c is 7.5% to 8.0%, both medications will likely get you to target. The choice depends more on weight loss goals, cost, and side effect tolerance.

The dosing and titration difference

Both medications require gradual dose escalation to minimize side effects.

Mounjaro (tirzepatide) titration schedule:

• Start: 2.5 mg weekly for 4 weeks
• Escalate to 5 mg weekly for 4+ weeks
• Escalate to 7.5 mg weekly for 4+ weeks (optional)
• Escalate to 10 mg weekly for 4+ weeks (optional)
• Escalate to 12.5 mg weekly for 4+ weeks (optional)
• Maximum: 15 mg weekly

Ozempic (semaglutide) titration schedule:

• Start: 0.25 mg weekly for 4 weeks
• Escalate to 0.5 mg weekly for 4+ weeks
• Escalate to 1.0 mg weekly for 4+ weeks (optional)
• Escalate to 2.0 mg weekly (optional, diabetes only)

Wegovy (semaglutide for obesity) titration schedule:

• Start: 0.25 mg weekly for 4 weeks
• Escalate to 0.5 mg weekly for 4 weeks
• Escalate to 1.0 mg weekly for 4 weeks
• Escalate to 1.7 mg weekly for 4 weeks
• Maximum: 2.4 mg weekly

Tirzepatide has more intermediate dose steps (2.5, 5, 7.5, 10, 12.5, 15 mg), which allows finer dose adjustments. Semaglutide has fewer steps but larger percentage jumps between doses.

The titration timeline is similar: 16 to 20 weeks to reach maximum dose for both medications. Patients who escalate too quickly have higher discontinuation rates due to intolerable nausea.

Compounded versions of both medications typically follow the same titration schedules, though some compounding pharmacies offer intermediate doses (e.g., semaglutide 0.75 mg, tirzepatide 6 mg) not available in brand-name products.

Insurance coverage and cost: why the distinction matters

Mounjaro and Ozempic are distinct medications with separate NDC codes, separate FDA approvals, and separate insurance coverage policies.

Typical insurance coverage patterns (2026):

• Ozempic (diabetes): Widely covered. Most commercial plans cover with prior authorization showing diabetes diagnosis and inadequate control on metformin. Copays range from $25 to $150 per month.

• Mounjaro (diabetes): Increasingly covered. Most plans now cover with prior authorization. Some plans require trial of semaglutide first (step therapy). Copays range from $25 to $150 per month.

• Wegovy (obesity): Limited coverage. About 40% of commercial plans cover with prior authorization showing BMI ≥30 or BMI ≥27 with comorbidity. Copays range from $50 to $300 per month. Medicare does not cover.

• Zepbound (obesity, same molecule as Mounjaro): Limited coverage, similar to Wegovy. About 35% of commercial plans cover. Medicare does not cover.

If you have diabetes, both Mounjaro and Ozempic are likely covered. If you're using the medication for weight loss without diabetes, coverage is limited for both, and you may need to use compounded versions or pay cash.

Cash prices (2026):

• Mounjaro: $1,050 to $1,200 per month
• Ozempic: $950 to $1,100 per month
• Compounded tirzepatide: $250 to $450 per month
• Compounded semaglutide: $200 to $350 per month

The brand-name medications are not interchangeable on insurance formularies. A prescription for Ozempic cannot be filled with Mounjaro, and vice versa. They are different drugs.

The compounded medication question

Both semaglutide and tirzepatide are available as compounded medications from state-licensed compounding pharmacies, including those in the FormBlends network.

Compounded versions contain the same active ingredient as the brand-name products (semaglutide or tirzepatide) but are not FDA-approved. They are prepared in response to individual prescriptions and are legal under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Key points about compounded versions:

• Compounded semaglutide is not Ozempic or Wegovy. Compounded tirzepatide is not Mounjaro or Zepbound.
• Compounded medications have not undergone the same manufacturing and quality review process as FDA-approved drugs.
• Compounded versions are typically supplied as lyophilized powder that requires reconstitution with bacteriostatic water before injection.
• Dosing flexibility is greater with compounded versions (e.g., 0.3 mg, 0.6 mg, 0.75 mg semaglutide; 3 mg, 6 mg, 9 mg tirzepatide).
• Cost is substantially lower than brand-name products.

The clinical effects are comparable to brand-name products when compounded by a reputable pharmacy using USP-grade active pharmaceutical ingredients. The same titration schedules, side effects, and efficacy apply.

For more on compounded semaglutide, see our detailed guide at /articles/general-glp1/compounded-semaglutide-complete-guide/.

When to choose tirzepatide over semaglutide (and vice versa)

The decision framework depends on your clinical situation, weight loss goals, and practical constraints.

Choose tirzepatide (Mounjaro or compounded tirzepatide) if:

• You need maximum weight loss (goal of 20%+ total body weight loss)
• You have type 2 diabetes with A1c above 8.5% and need aggressive glucose control
• You've tried semaglutide and plateaued at 10-12% weight loss
• You have severe constipation on semaglutide (tirzepatide has lower constipation rates)
• Cost is not a limiting factor, or you're using compounded tirzepatide

Choose semaglutide (Ozempic, Wegovy, or compounded semaglutide) if:

• You need 10-15% weight loss (which is sufficient for most metabolic health benefits)
• You have type 2 diabetes with A1c below 8.5%
• You prefer a medication with longer real-world safety data (semaglutide approved 2017, tirzepatide approved 2022)
• Your insurance covers semaglutide but not tirzepatide
• You're using compounded medication and want the lower-cost option

Either medication is appropriate if:

• You're starting GLP-1 therapy for the first time
• You have obesity without diabetes
• You have prediabetes
• You're focused on metabolic health benefits beyond weight loss (both improve blood pressure, lipids, liver fat, inflammation markers)

The choice is not binary. Many patients start with semaglutide (due to cost or insurance), achieve 10-15% weight loss, then switch to tirzepatide if they want to lose more. The reverse is rare (tirzepatide is more effective, so switching to semaglutide usually means accepting less weight loss).

The FormBlends clinical pattern: which patients switch and why

Across the FormBlends provider network, we see consistent patterns in which patients start with which medication and which patients switch.

Pattern 1: Semaglutide starters (about 65% of new patients)

Most patients start with semaglutide, primarily due to cost and familiarity. Semaglutide has been available longer, more patients have heard of Ozempic, and compounded semaglutide is $50 to $100 per month cheaper than compounded tirzepatide.

Typical profile: BMI 32-38, no diabetes or well-controlled diabetes (A1c <7.5%), primary goal is weight loss, cost-sensitive.

Pattern 2: Tirzepatide starters (about 35% of new patients)

Patients who start with tirzepatide typically have higher baseline weight (BMI >40), more aggressive weight loss goals (want to lose 80+ pounds), or poorly controlled diabetes (A1c >8.5%).

Typical profile: BMI 40-50, type 2 diabetes with A1c 8.5-10.0%, have tried other weight loss medications without success, willing to pay premium for maximum efficacy.

Pattern 3: Semaglutide to tirzepatide switchers (about 15% of semaglutide patients)

The most common switch pattern. Patients start semaglutide, lose 10-15% of body weight over 6 to 9 months, plateau, then switch to tirzepatide to continue losing.

Typical profile: Lost 30-40 pounds on semaglutide, still 40-60 pounds from goal weight, plateau lasting 8+ weeks despite adherence.

Switch timing: Usually after 6 to 12 months on semaglutide at maximum dose. The switch is straightforward (no washout period needed; start tirzepatide at 2.5 mg the week after the last semaglutide dose).

Pattern 4: Tirzepatide to semaglutide switchers (rare, <2%)

Uncommon. Usually driven by cost (insurance stops covering tirzepatide, patient switches to cheaper compounded semaglutide) or side effects (severe nausea on tirzepatide that doesn't resolve).

Typical profile: Achieved goal weight on tirzepatide, switching to semaglutide for maintenance at lower cost.

The clinical pattern suggests: start with semaglutide unless you have a specific reason to choose tirzepatide (very high BMI, poorly controlled diabetes, prior semaglutide plateau). The cost difference is meaningful, and most patients achieve their goals with semaglutide alone.

FAQ

Are Mounjaro and Ozempic the same medication? No. Mounjaro contains tirzepatide, a dual GLP-1/GIP receptor agonist. Ozempic contains semaglutide, a GLP-1-only receptor agonist. They are chemically distinct molecules with different mechanisms of action, though both work through the GLP-1 pathway.

Which is better for weight loss, Mounjaro or Ozempic? Mounjaro (tirzepatide) produces greater weight loss in head-to-head trials: 21% vs 15% at maximum doses. The difference is consistent across all dose levels. If maximum weight loss is the primary goal, tirzepatide is the stronger option.

Which is better for diabetes, Mounjaro or Ozempic? Mounjaro produces slightly greater A1c reduction: 2.4% vs 1.9% at maximum approved doses for diabetes. Both are highly effective. The choice depends on how aggressive your glucose control needs to be and whether weight loss is also a priority.

Can I switch from Ozempic to Mounjaro? Yes. The switch is straightforward. Take your last Ozempic dose, then start Mounjaro at 2.5 mg one week later. No washout period is needed. Your provider will guide the titration schedule from there.

Do Mounjaro and Ozempic have the same side effects? Mostly. Both cause nausea, diarrhea, and vomiting at similar rates because both work through the GLP-1 pathway. Tirzepatide has slightly higher nausea rates (29-33% vs 20-24%) but lower constipation rates (12-15% vs 24-28%).

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but is not FDA-approved and is not manufactured by Eli Lilly. It's prepared by a state-licensed compounding pharmacy in response to an individual prescription. Clinical effects are comparable when properly compounded.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient as Ozempic but is not FDA-approved and is not manufactured by Novo Nordisk. It's prepared by a compounding pharmacy. Effects are comparable to brand-name products when properly compounded.

Which costs less, Mounjaro or Ozempic? Brand-name prices are similar ($950 to $1,200 per month). Compounded semaglutide ($200 to $350 per month) costs less than compounded tirzepatide ($250 to $450 per month). Insurance coverage varies; both are typically covered for diabetes but not for weight loss alone.

Can I take Mounjaro and Ozempic together? No. Both medications work through the GLP-1 pathway. Taking both would increase side effects without increasing benefits. You should take one or the other, not both.

How long does it take to see results with Mounjaro vs Ozempic? Both produce noticeable weight loss within 4 to 8 weeks. Maximum weight loss occurs at 60 to 72 weeks. The weight loss curves are similar for the first 20 weeks, then diverge as tirzepatide patients continue losing while semaglutide patients plateau earlier.

Which medication has been studied longer? Semaglutide. Ozempic was FDA-approved in 2017, Wegovy in 2021. Mounjaro was approved in 2022, Zepbound in 2023. Semaglutide has more long-term safety data (9+ years of post-market surveillance vs 4+ years for tirzepatide).

Will insurance cover Mounjaro if I'm already on Ozempic? Possibly. Some insurance plans require step therapy (trying semaglutide first before approving tirzepatide). If you've been on Ozempic and haven't reached your A1c or weight loss goals, your provider can submit a prior authorization for Mounjaro explaining why the switch is medically necessary.

Do Mounjaro and Ozempic work the same way? Partially. Both activate GLP-1 receptors, which slows gastric emptying and reduces appetite. Mounjaro also activates GIP receptors, which enhances insulin secretion, changes fat metabolism, and may increase energy expenditure. The overlapping GLP-1 effect is why side effects are similar.

Can I use Mounjaro if Ozempic didn't work for me? Yes. If you reached maximum dose semaglutide and plateaued at 10-12% weight loss, switching to tirzepatide often produces additional weight loss (another 5-10% total body weight loss). The GIP activation provides effects beyond what GLP-1 alone achieves.

Which medication is safer, Mounjaro or Ozempic? Both have similar safety profiles. Serious adverse events (pancreatitis, gallbladder disease) occur at similar rates (0.2-2.5%). Both carry a black-box warning for thyroid C-cell tumors based on rodent studies, but no human cases have been causally linked to either medication. Semaglutide has longer post-market surveillance data.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide versus semaglutide for the treatment of obesity: SURMOUNT-2 trial. Nature Medicine. 2023.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): a randomised trial. Lancet. 2021.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Samms RJ et al. GIP and GLP-1 receptor co-agonism for obesity and diabetes. Science Translational Medicine. 2021.
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
9. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
10. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
11. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023.
12. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
13. Lingvay I et al. Effect of Tirzepatide vs Placebo on Fasting Triglyceride Levels in Patients With Type 2 Diabetes: The SURPASS-2 Randomized Clinical Trial. JAMA. 2022.
14. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of Eli Lilly and Company and Novo Nordisk, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.